Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression

Michael Maes

doi:10.1007/s11011-012-9326-6

Related publications

Article2020

The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach

Gerwyn Morris, Chiara C. Bortolasci, Basant K. Puri, Lisa Olive, Wolfgang Marx, Adrienne O’Neil, Eugene Athan, André F. Carvalho, Michael Maes, Ken Walder, Michael Berk

Article2014

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Cristiano Noto, Lucas B. Rizzo, Rodrigo B. Mansur, Roger S. McIntyre, Michael Maes, Elisa Brietzke

Letter2023

Although serotonin is not a major player in depression, its precursor is

Abbas F. Almulla, Michael Maes

Preprint2023

Major depression is not an inflammatory disorder: depletion of the compensatory immunoregulatory system is a hallmark of a mild depression phenotype

Michael Maes, Asara Vasupanrajit, Ketsupar Jirakran, Bo Zhou, Chavit Tunvirachaisakul, Abbas F. Almulla

Article2022

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status

Javier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, Nicholas J. Clemons, Kenji M. Fujihara, Thomas Riseborough, Amina F.A.S. Teunisse, Aart G. Jochemsen, Lars Abrahmsén, Giovanni Blandino, Andrea Russo, Cristina Gamell, Stephen B. Fox, Catherine Mitchell, Elena A. Takano, David J. Byrne, Panimaya Jeffreena Miranda, Reem Saleh, Heather Thorne, Shahneen Sandhu, Scott Williams, Simon P. Keam, Ygal Haupt,